LBPMedicine(SH:688393) Zhong Guo Jing Ji Wang·2025-09-16 08:16Core Points - Anbiping (688393.SH) reported a significant decline in revenue and net profit for the first half of 2025, with revenue at 159 million yuan, down 30.11% year-on-year, and a net profit attributable to shareholders of -12.5 million yuan compared to a profit of 16.4 million yuan in the same period last year [1] - The company has experienced a continuous decline in net profit for four consecutive years, with net profits of 84.7 million yuan in 2020, decreasing to 21.3 million yuan in 2024 [1] - Anbiping was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 20, 2020, with an initial issuance of 23.34 million shares at a price of 30.56 yuan per share [1] Financial Performance - For the first half of 2025, Anbiping's net profit excluding non-recurring gains and losses was -14.7 million yuan, down from 10.5 million yuan in the previous year [1] - The company's operating cash flow improved to 19.0 million yuan, compared to -11.3 million yuan in the same period last year [1] - Historical net profits from 2020 to 2024 show a downward trend, with figures of 84.7 million yuan, 79.8 million yuan, 42.7 million yuan, 40.1 million yuan, and 21.3 million yuan respectively [1] IPO and Stock Performance - Anbiping's initial public offering raised a total of 713 million yuan, with a net amount of 640 million yuan after deducting issuance costs, exceeding the original plan by 266 million yuan [2] - The company’s stock reached a peak price of 74.00 yuan on its first trading day but is currently in a state of decline [2] - The funds raised were intended for the construction of a research and production base and the upgrade of the marketing service network [2]